The board of directors of Kintor Pharmaceutical Limited released the final results (the "Final Results") for male patients from the Clinical Trail (ClinicalTrials.gov identifier: NCT04446429) of Proxalutamide for the treatment of COVID-19. The Final Results showed that Proxalutamide could significantly inhibit the transition of condition of male patients infected with COVID-19 from mild to severe and had good safety for short-term administration (15 days). The Clinical Trial is a randomised, double-blind and placebo-controlled clinical trial, designed to explore the efficacy of Proxalutamide in the treatment of COVID-19, and with an aim to accelerate the turning of rtPCR test positive to rtPCR test negative and prevent the transition of the patients' condition from mild to severe by inhibiting the replication and reproduction of the SARS-CoV-2 coronavirus. The primary endpoints of the Clinical Trial include the hospitalisation rate, percentage of ICU (intensive care unit) usage, mechanical ventilation usage and death within 30 days and the evaluation of clinical symptoms. The Final Results included data of 134 male patients in the Proxalutamide Arm and 128 male patients in the Controlled Arm, which showed that no patients were hospitalised in the Proxalutamide Arm (0%), as compared to 35 patients were hospitalised in the Controlled Arm (27.3%) due to the worsening of the patients' condition. The Final Results showed that Proxalutamide could significantly reduce the hospitalisation rate of patients infected with COVID-19 and no adverse events related to Proxalutamide were observed during the Clinical Trial. The hospitalisation rate, percentage of ICU usage, mechanical ventilation usage and death within 30 days in the Proxalutamide Arm was 0%, 0%, 0% and 0%, respectively, compared to 27.3%, 14.1%, 10.2% and 1.6% in the Controlled Arm. The Group is also conducting the Clinical Trial for female patients infected with COVID-19 in Brazil with an aim to enroll a total of 168 patients. The Board is pleased to release the interim results (the "Interim Results") for female patients from the Clinical Trial as of 7 January 2021. The Interim Results included data of 60 female patients in the Proxalutamide Arm and 35 female patients in the Controlled Arm, and the patients were menopausal female over 50 years old who were tested rtPCR positive within the past seven days. The hospitalisation rate, percentage of ICU usage, mechanical ventilation usage and death in 30 days in the Proxalutamide Arm was 1.7%, 0%, 0% and 0%, respectively, compared to 17.1%, 8.6%, 5.7% and 2.9% in the Controlled Arm. Proxalutamide is a androgen receptor (AR) antagonist that can limit the expression of ACE-2 and TMPRSS2, which play a critical role for SARS-CoV-2 to bind and enter host cells in the lung. Although the female patients have lower androgen and AR expression as compared to the male patients, the Interim Results showed that Proxalutamide could still significantly inhibit the transition of condition of female patients infected with COVID-19 from mild or moderate to severe. The Group expects to conclude the enrolment of the Clinical Trial for female patients in February 2021 and finalised the data collection by March 2021.